Objectives: To define risk following systemic/intravascular administration of adipose-derived stromal vascular fraction (SVF) and cultured cells derived from SVF.

Introduction: The stromal vascular fraction of adipose tissue has considerable clinical potential due, in part, to the heterogeneity of its cellular composition. However, this population is derived by the digestion of a three dimensional tissue (adipose). This creates special concerns when the cell product is to be delivered into the vascular system with the consequent risk of embolism and stimulation of platelet aggregation.

Materials / method: Not applicable

Results: Risks derive from both byproducts of tissue disaggregation and from the cells themselves. By-products with risk include: tissue aggregates from incomplete disaggregation; collagen fragments; extracellular lipids; and extracellular DNA. SVF cells include vascular endothelial cells, smooth muscle cells, fibroblasts, stem cells, and leukocytes. Some of these cell types express Tissue Factor which plays a key role in the clotting process. Tissue Factor is also highly expressed in cultured cell populations derived from SVF, in particular, adipose-derived stem or stromal cells (ADSCs).

Conclusion: Systemic administration of SVF or cells derived by culture of SVF must take each of these risks into consideration and apply systems and processes by which risk is eliminated or managed, the success of these approaches in adequately mitigating these risks must also be demonstrated in in vivo preclinical testing before the SVF or SVF-derived product may be used clinically.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
Yes
Please specify entities (individual, company, society): Cytori KK (Japan; Consultant)

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Objectives: A review of how far away we are to culture fat for injections in aesthetic and cosmetic procedures.

Introduction: Fat or commonly called liquid gold is used in different cosmetic procedures for both body and face. Fat gives volume but also contains regenerative cells and stem cells making fat transfer one of the modalities with best result for skin and tissue regeneration. But how far away are we to culture fat not needing to harvest through liposuction?

Materials / method: Fattransfer demands liposuction to harvest the fat which for many patients is one reason to choose another procedure such as HA-fillers. Also one of the main limitations of fat transfers is that it is the patient who comes with the resources. This means that patients seeking for large volume transplantations need to gain weight preoperatively which will have other affects on the constitution of the patients body.

Results: Here is a littérature review of how far away we are to culture fat for facial and body injections

Conclusion: Fat culture will be a part of our business in a near future, will it replace other fillers such as Hyaluronic Acid?
Aesthetic procedures will continue to develop and new techniques will definitely help us perform better and safer procedures for our patients.

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability